PMID- 24249433
OWN - NLM
STAT- MEDLINE
DCOM- 20150202
LR  - 20220325
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 30
IP  - 11
DP  - 2013 Nov
TI  - Vandetanib in advanced medullary thyroid cancer: review of adverse event 
      management strategies.
PG  - 945-66
LID - 10.1007/s12325-013-0069-5 [doi]
AB  - INTRODUCTION: Vandetanib has recently demonstrated clinically meaningful benefits 
      in patients with unresectable, locally advanced or metastatic medullary thyroid 
      cancer (MTC). Given the potential for long-term vandetanib therapy in this 
      setting, in addition to treatment for disease-related symptoms, effective 
      management of related adverse events (AEs) is vital to ensure patient compliance 
      and maximize clinical benefit with vandetanib therapy. METHODS: This expert 
      meeting-based review aims to summarize published data on AEs associated with 
      vandetanib therapy and to provide clinicians with specific practical guidance on 
      education, monitoring, and management of toxicities induced in patients treated 
      with vandetanib in advanced and metastatic MTC. The content of this review is 
      based on the expert discussions from a multidisciplinary meeting held in October 
      2012. RESULTS: Characteristics, frequency, and risk data are outlined for a 
      number of dermatological, cardiovascular, gastrointestinal, and general AEs 
      related to vandetanib treatment. Preventive strategies, practical treatment 
      suggestions, and points for clinical consideration are provided. CONCLUSIONS: 
      Good patient and team communication is necessary for the prevention, early 
      detection, and management of AEs of vandetanib. Physicians, nurses, and other 
      healthcare providers play a critical role in providing AE management and patient 
      support to optimize outcomes with vandetanib in MTC.
FAU - Grande, Enrique
AU  - Grande E
AD  - Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo 
      Km. 9.100, 28034, Madrid, Spain, egrande@oncologiahrc.com.
FAU - Kreissl, Michael C
AU  - Kreissl MC
FAU - Filetti, Sebastiano
AU  - Filetti S
FAU - Newbold, Kate
AU  - Newbold K
FAU - Reinisch, Walter
AU  - Reinisch W
FAU - Robert, Caroline
AU  - Robert C
FAU - Schlumberger, Martin
AU  - Schlumberger M
FAU - Tolstrup, Laerke K
AU  - Tolstrup LK
FAU - Zamorano, Jose L
AU  - Zamorano JL
FAU - Capdevila, Jaume
AU  - Capdevila J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131119
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Piperidines)
RN  - 0 (Quinazolines)
RN  - YO460OQ37K (vandetanib)
RN  - Thyroid cancer, medullary
MH  - Carcinoma, Neuroendocrine
MH  - Cardiovascular Diseases/chemically induced/physiopathology/therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Eruptions/etiology/physiopathology/therapy
MH  - Drug-Related Side Effects and Adverse Reactions/radiotherapy/*therapy
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced/physiopathology/therapy
MH  - Humans
MH  - Male
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Staging
MH  - Patient Selection
MH  - Piperidines/*adverse effects/therapeutic use
MH  - Prognosis
MH  - Quinazolines/*adverse effects/therapeutic use
MH  - Risk Assessment
MH  - Thyroid Neoplasms/*drug therapy/mortality/pathology
MH  - Treatment Outcome
PMC - PMC3898148
EDAT- 2013/11/20 06:00
MHDA- 2015/02/03 06:00
PMCR- 2013/11/19
CRDT- 2013/11/20 06:00
PHST- 2013/09/24 00:00 [received]
PHST- 2013/11/20 06:00 [entrez]
PHST- 2013/11/20 06:00 [pubmed]
PHST- 2015/02/03 06:00 [medline]
PHST- 2013/11/19 00:00 [pmc-release]
AID - 69 [pii]
AID - 10.1007/s12325-013-0069-5 [doi]
PST - ppublish
SO  - Adv Ther. 2013 Nov;30(11):945-66. doi: 10.1007/s12325-013-0069-5. Epub 2013 Nov 
      19.